Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
- ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
- Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
Tweets from GSK
-
GSK @GSK
Our scientists are working hard to find candidate vaccines more quickly and revolutionise the way vaccines are manufactured. Find out how… twitter.com/BBCBusiness/st…
about 8 hours ago
-
GSK @GSK
We recognise the need for continued research and treatment options for all #cancer patients. That’s why we’re proud to be working with organisations like @theMMRF and @cure_magazine to help raise awareness and funds for #myeloma research. #ASH19 #MM4MM #mmsm
about 10 hours ago -
GSK @GSK
Hello from the ASH Dash! We’re proud to sponsor today’s @ASH_hematology Foundation Run/Walk during #ASH19 -- raising funds to support multiple #myeloma research. Way to go everyone! #mmsm
about 1 day ago
